February 3, 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. The start-up's technology enables the automated production of CAR T and other cell therapies at scale. With CSEM's help, Limula has moved its technology beyond prototyping towards pre-industrial stage.

Limula team
© CSEM - Successful collaboration between start-up Limula and the Swiss technology innovation center CSEM: Yann Pierson (Limula, CTO), Vincent Revol (CSEM, Co-Head Research & Business Development Life Science Technologies at CSEM), Diane Ledroit (CSEM, Senior Engineer Cell Microtechnologies), Luc Henry (Limula), and Gilles Weder (CSEM, Co-Head Research & Business Development Life Science Technologies at CSEM). They hold a disposable Limula Kit in their hands (from left to right).

Related Press

Alithea team

16 May 2023

Democratizing RNA sequencing: A breakthrough in cost and efficiency

CSEM helped Alithea Genomics to create a technique that can handle hundreds of RNA samples in a single tube, resulting in a significant decrease in reagents and manual effort in the overall workflow....

Group of 7 persons, members of the CSEM and the TheraMe teams

23 January 2025

CSEM and TheraMe! revolutionize cancer therapy with personalized drug screening technology

What if there was a solution allowing to test which drug or drug combination works best on the tumor cells of a given patient at any given stage of the disease?...

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....